282 related articles for article (PubMed ID: 30021699)
1. Biomolecular Consequences of Platelet Pathogen Inactivation Methods.
Feys HB; Van Aelst B; Compernolle V
Transfus Med Rev; 2019 Jan; 33(1):29-34. PubMed ID: 30021699
[TBL] [Abstract][Full Text] [Related]
2. Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus.
Prudent M; D'Alessandro A; Cazenave JP; Devine DV; Gachet C; Greinacher A; Lion N; Schubert P; Steil L; Thiele T; Tissot JD; Völker U; Zolla L
Transfus Med Rev; 2014 Apr; 28(2):72-83. PubMed ID: 24685438
[TBL] [Abstract][Full Text] [Related]
3. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
4. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
[TBL] [Abstract][Full Text] [Related]
5. Peculiarities of studying the effects of pathogen reduction technologies on platelets.
Osman A; Hitzler WE; Provost P
Proteomics Clin Appl; 2016 Aug; 10(8):805-15. PubMed ID: 27095411
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
[TBL] [Abstract][Full Text] [Related]
7. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
8. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
[TBL] [Abstract][Full Text] [Related]
9. Pathogen reduction technologies: The pros and cons for platelet transfusion.
Magron A; Laugier J; Provost P; Boilard E
Platelets; 2018 Jan; 29(1):2-8. PubMed ID: 28523956
[TBL] [Abstract][Full Text] [Related]
10. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
[TBL] [Abstract][Full Text] [Related]
11. Improving the bacteriological safety of platelet transfusions.
Blajchman MA; Goldman M; Baeza F
Transfus Med Rev; 2004 Jan; 18(1):11-24. PubMed ID: 14689374
[TBL] [Abstract][Full Text] [Related]
12. Current debate on pathogen inactivation of platelet concentrates--to use or not to use?
Hervig T; Seghatchian J; Apelseth TO
Transfus Apher Sci; 2010 Dec; 43(3):411-414. PubMed ID: 21075686
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen.
Cazenave JP; Aleil B; Wiesel ML; Laforêt M; Isola H
Vox Sang; 2004 Apr; 86(3):201-2. PubMed ID: 15078258
[No Abstract] [Full Text] [Related]
14. Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions.
Arnason NA; Johannson F; Landrö R; Hardarsson B; Irsch J; Gudmundsson S; Rolfsson O; Sigurjonsson OE
Transfusion; 2019 Dec; 59(12):3727-3735. PubMed ID: 31674051
[TBL] [Abstract][Full Text] [Related]
15. Bacterial contamination of platelets for transfusion: strategies for prevention.
Levy JH; Neal MD; Herman JH
Crit Care; 2018 Oct; 22(1):271. PubMed ID: 30367640
[TBL] [Abstract][Full Text] [Related]
16. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
Seghatchian J; Hervig T; Putter JS
Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
[TBL] [Abstract][Full Text] [Related]
17. Differential Expression Analysis by RNA-Seq Reveals Perturbations in the Platelet mRNA Transcriptome Triggered by Pathogen Reduction Systems.
Osman A; Hitzler WE; Ameur A; Provost P
PLoS One; 2015; 10(7):e0133070. PubMed ID: 26172280
[TBL] [Abstract][Full Text] [Related]
18. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
van Rhenen D; Gulliksson H; Cazenave JP; Pamphilon D; Ljungman P; Klüter H; Vermeij H; Kappers-Klunne M; de Greef G; Laforet M; Lioure B; Davis K; Marblie S; Mayaudon V; Flament J; Conlan M; Lin L; Metzel P; Buchholz D; Corash L;
Blood; 2003 Mar; 101(6):2426-33. PubMed ID: 12456508
[TBL] [Abstract][Full Text] [Related]
19. [Conventional vs pathogen-inactivated platelet concentrates for the treatment of perioperative coagulopathy. A prospective cohort study].
Weber CF; Meininger D; Byhahn C; Seifried E; Zacharowski K; Adam E; Henschler R; Müller MM
Chirurg; 2011 Apr; 82(4):348-58. PubMed ID: 21249326
[TBL] [Abstract][Full Text] [Related]
20. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
Ambruso DR; Thurman G; Marschner S; Goodrich RP
Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
